Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.
Video content above is prompted by the following:
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More